Retatrutide Phase 3: 71 lbs Weight Loss + Knee Pain Relief | Denver
Eli Lilly’s triple-action GLP-1 drug delivered striking results in the Phase III TRIUMPH-4 trial — and the knee pain data might be the most remarkable part.
—
If you’ve been watching the GLP-1 space, retatrutide isn’t news. But the Phase III data released this week from Eli Lilly’s TRIUMPH-4 trial is worth your attention.
Retatrutide is the first triple hormone receptor agonist — it hits GLP-1, GIP, and glucagon receptors simultaneously. Think of it as the upgrade you’d expect after tirzepatide (Zepbound/Mounjaro) proved that hitting two receptors beats one. Now add glucagon into the mix.
The weight loss numbers were loud: Participants with obesity and knee osteoarthritis lost an average of 71.2 pounds over 68 weeks. That’s not a rounding error. That’s a clinically meaningful dataset.
But here’s what caught my eye as an obesity medicine physician: The knee pain results.
Pain scores dropped roughly 75%. And here’s the kicker — more than one in eight trial participants were completely pain-free by the end of the study. Gone. No more knee pain. That doesn’t happen with weight loss alone, and the researchers know it.
Why does retatrutide reduce joint pain beyond what you’d expect from losing 71 pounds? The leading theory involves the glucagon receptor. Glucagon affects energy metabolism in ways that appear to reduce systemic inflammation — including in joint tissue. The exact mechanism is still being worked out, but the signal is real.
Colorado context: Our state has one of the highest rates of active outdoor recreation in the country. Hikers, skiers, runners — the people doing the damage are also the ones most motivated to fix it. Knee osteoarthritis and obesity are a common combination I see in my Greenwood Village practice. For these patients, retatrutide — if approved — could be the first drug that meaningfully addresses both problems at once.
Seven additional Phase III retatrutide readouts are expected in 2026. That’s not a guarantee of approval, but it’s a strong signal that Eli Lilly is building a comprehensive data package.
Clinical takeaway: Retatrutide is not yet FDA-approved. But if you’re a patient with obesity and knee osteoarthritis — especially if you’ve tried other GLP-1 drugs without adequate joint relief — ask your physician whether retatrutide trials or eventual approval might be relevant to your case.
We’ll be watching the Phase III readouts closely.
—
Eli Lilly’s retatrutide was featured in Clarivate’s Drugs to Watch 2026 report. Phase III TRIUMPH-4 trial (NCT05869903). Full FDA approval timeline has not been announced.